Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma
度伐利尤单抗(抗PD-L1)联合来那度胺治疗复发/难治性皮肤T细胞淋巴瘤的I期临床试验
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024014655
Querfeld, Christiane; Palmer, Joycelynne; Han, Zhen; Wu, Xiwei; Yuan, Yate-Ching; Chen, Min-Hsuan; Su, Chingyu; Tsai, Ni-Chun; Smith, D Lynne; Hammond, Samantha N; Crisan, Liliana; Song, Joo Y; Pillai, Raju; Rosen, Steven T; Zain, Jasmine
T细胞
淋巴瘤
PD-L1
T细胞
细胞生物学
免疫/内分泌